NEW YORK – Tempus AI on Wednesday said it will collaborate with Genialis to develop new RNA-based biomarker algorithms to help predict treatment response across multiple cancer types.
Under the multiyear agreement, Genialis will use Tempus' multimodal dataset to validate its artificial intelligence-based foundation model that uses data from approximately 1 million RNA sequencing samples. The Genialis TM Supermodel "yields accurate and information-rich biomarker algorithms to help biopharma improve therapeutic development," Tempus said in a statement.
Genialis will use Tempus' analytics platform Lens to validate biomarker signatures to bring clinical algorithms to market, while Tempus will gain the right to evaluate and potentially license these algorithms for commercialization as part of Tempus' xR platform.
Tempus' dataset has already been used to independently validate Genialis' KrasID algorithm that predicts patient response to KRAS-targeted therapies across cancer types and driver mutations, Tempus noted.
"Biomarkers have the potential to transform how cancer is diagnosed and treated, but today's standard of care leaves a lot to be desired in terms of accuracy, information richness, and patient reach," Genialis CEO Rafael Rosengarten said in a statement. "With this strategic agreement with Tempus, Genialis will have access to an unparalleled data resource to validate our cutting-edge patient classifiers."